<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1998-12-15" modified="2017-05-10" version="195">
<accession>Q15303</accession>
<accession>B7ZLD7</accession>
<accession>B7ZLE2</accession>
<accession>B7ZLE3</accession>
<accession>Q2M1W1</accession>
<accession>Q59EW4</accession>
<name>ERBB4_HUMAN</name>
<protein>
<recommendedName>
<fullName>Receptor tyrosine-protein kinase erbB-4</fullName>
<ecNumber>2.7.10.1</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Proto-oncogene-like protein c-ErbB-4</fullName>
</alternativeName>
<alternativeName>
<fullName>Tyrosine kinase-type cell surface receptor HER4</fullName>
</alternativeName>
<alternativeName>
<fullName>p180erbB4</fullName>
</alternativeName>
<component>
<recommendedName>
<fullName>ERBB4 intracellular domain</fullName>
<shortName>4ICD</shortName>
<shortName>E4ICD</shortName>
</recommendedName>
<alternativeName>
<fullName>s80HER4</fullName>
</alternativeName>
</component>
</protein>
<gene>
<name type="primary">ERBB4</name>
<name type="synonym">HER4</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1993" name="Proc. Natl. Acad. Sci. U.S.A." volume="90" first="1746" last="1750">
<title>Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.</title>
<authorList>
<person name="Plowman G.D."/>
<person name="Culouscou J.-M."/>
<person name="Whitney G.S."/>
<person name="Green J.M."/>
<person name="Carlton G.W."/>
<person name="Foy L."/>
<person name="Neubauer M.G."/>
<person name="Shoyab M."/>
</authorList>
<dbReference type="PubMed" id="8383326"/>
<dbReference type="DOI" id="10.1073/pnas.90.5.1746"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1)</scope>
<scope>FUNCTION AS CELL SURFACE RECEPTOR</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>TISSUE SPECIFICITY</scope>
<source>
<tissue>Mammary carcinoma</tissue>
</source>
</reference>
<reference key="2">
<citation type="journal article" date="1997" name="J. Biol. Chem." volume="272" first="26761" last="26768">
<title>A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester.</title>
<authorList>
<person name="Elenius K."/>
<person name="Corfas G."/>
<person name="Paul S."/>
<person name="Choi C.J."/>
<person name="Rio C."/>
<person name="Plowman G.D."/>
<person name="Klagsbrun M."/>
</authorList>
<dbReference type="PubMed" id="9334263"/>
<dbReference type="DOI" id="10.1074/jbc.272.42.26761"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1)</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND BTC</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
<source>
<tissue>Fetal brain</tissue>
</source>
</reference>
<reference key="3">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B CYT-1; JM-A CYT-2 AND JM-B CYT-2)</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="4">
<citation type="submission" date="2005-03" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Totoki Y."/>
<person name="Toyoda A."/>
<person name="Takeda T."/>
<person name="Sakaki Y."/>
<person name="Tanaka A."/>
<person name="Yokoyama S."/>
<person name="Ohara O."/>
<person name="Nagase T."/>
<person name="Kikuno R.F."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A CYT-2)</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="5">
<citation type="journal article" date="1993" name="J. Biol. Chem." volume="268" first="18407" last="18410">
<title>Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor.</title>
<authorList>
<person name="Culouscou J.-M."/>
<person name="Plowman G.D."/>
<person name="Carlton G.W."/>
<person name="Green J.M."/>
<person name="Shoyab M."/>
</authorList>
<dbReference type="PubMed" id="7689552"/>
</citation>
<scope>INTERACTION WITH NRG1</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="6">
<citation type="journal article" date="1993" name="Nature" volume="366" first="473" last="475">
<title>Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.</title>
<authorList>
<person name="Plowman G.D."/>
<person name="Green J.M."/>
<person name="Culouscou J.M."/>
<person name="Carlton G.W."/>
<person name="Rothwell V.M."/>
<person name="Buckley S."/>
</authorList>
<dbReference type="PubMed" id="7902537"/>
<dbReference type="DOI" id="10.1038/366473a0"/>
</citation>
<scope>INTERACTION WITH NRG1</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1996" name="J. Biol. Chem." volume="271" first="4813" last="4818">
<title>HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers.</title>
<authorList>
<person name="Cohen B.D."/>
<person name="Green J.M."/>
<person name="Foy L."/>
<person name="Fell H.P."/>
</authorList>
<dbReference type="PubMed" id="8617750"/>
<dbReference type="DOI" id="10.1074/jbc.271.9.4813"/>
</citation>
<scope>FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>PHOSPHORYLATION AT TYR-1056; TYR-1188 AND TYR-1242</scope>
<scope>INTERACTION WITH EGFR; SHC1 AND PIK3R1</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1996" name="Oncogene" volume="12" first="345" last="353">
<title>Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.</title>
<authorList>
<person name="Riese D.J. II"/>
<person name="Bermingham Y."/>
<person name="van Raaij T.M."/>
<person name="Buckley S."/>
<person name="Plowman G.D."/>
<person name="Stern D.F."/>
</authorList>
<dbReference type="PubMed" id="8570211"/>
</citation>
<scope>INTERACTION WITH BTC</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1997" name="EMBO J." volume="16" first="1268" last="1278">
<title>Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.</title>
<authorList>
<person name="Elenius K."/>
<person name="Paul S."/>
<person name="Allison G."/>
<person name="Sun J."/>
<person name="Klagsbrun M."/>
</authorList>
<dbReference type="PubMed" id="9135143"/>
<dbReference type="DOI" id="10.1093/emboj/16.6.1268"/>
</citation>
<scope>FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND IN ACTIVATION OF PIK3R1</scope>
<scope>INTERACTION WITH HBEGF AND PIK3R1</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1997" name="Nature" volume="387" first="512" last="516">
<title>Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.</title>
<authorList>
<person name="Carraway K.L. III"/>
<person name="Weber J.L."/>
<person name="Unger M.J."/>
<person name="Ledesma J."/>
<person name="Yu N."/>
<person name="Gassmann M."/>
<person name="Lai C."/>
</authorList>
<dbReference type="PubMed" id="9168115"/>
<dbReference type="DOI" id="10.1038/387512a0"/>
</citation>
<scope>INTERACTION WITH NRG2</scope>
<scope>FUNCTION AS NRG2 RECEPTOR</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1997" name="Oncogene" volume="15" first="2841" last="2848">
<title>Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.</title>
<authorList>
<person name="Komurasaki T."/>
<person name="Toyoda H."/>
<person name="Uchida D."/>
<person name="Morimoto S."/>
</authorList>
<dbReference type="PubMed" id="9419975"/>
<dbReference type="DOI" id="10.1038/sj.onc.1201458"/>
</citation>
<scope>INTERACTION WITH EREG</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1997" name="Proc. Natl. Acad. Sci. U.S.A." volume="94" first="9562" last="9567">
<title>Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4.</title>
<authorList>
<person name="Zhang D."/>
<person name="Sliwkowski M.X."/>
<person name="Mark M."/>
<person name="Frantz G."/>
<person name="Akita R."/>
<person name="Sun Y."/>
<person name="Hillan K."/>
<person name="Crowley C."/>
<person name="Brush J."/>
<person name="Godowski P.J."/>
</authorList>
<dbReference type="PubMed" id="9275162"/>
<dbReference type="DOI" id="10.1073/pnas.94.18.9562"/>
</citation>
<scope>INTERACTION WITH NRG3</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="7717" last="7724">
<title>Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3.</title>
<authorList>
<person name="Fiddes R.J."/>
<person name="Campbell D.H."/>
<person name="Janes P.W."/>
<person name="Sivertsen S.P."/>
<person name="Sasaki H."/>
<person name="Wallasch C."/>
<person name="Daly R.J."/>
</authorList>
<dbReference type="PubMed" id="9516479"/>
<dbReference type="DOI" id="10.1074/jbc.273.13.7717"/>
</citation>
<scope>INTERACTION WITH GRB7</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1999" name="J. Biol. Chem." volume="274" first="17209" last="17218">
<title>ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.</title>
<authorList>
<person name="Olayioye M.A."/>
<person name="Beuvink I."/>
<person name="Horsch K."/>
<person name="Daly J.M."/>
<person name="Hynes N.E."/>
</authorList>
<dbReference type="PubMed" id="10358079"/>
<dbReference type="DOI" id="10.1074/jbc.274.24.17209"/>
</citation>
<scope>INTERACTION WITH ERBB2</scope>
<scope>FUNCTION IN ACTIVATION OF STAT5A</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1999" name="Oncogene" volume="18" first="2607" last="2615">
<title>Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase.</title>
<authorList>
<person name="Elenius K."/>
<person name="Choi C.J."/>
<person name="Paul S."/>
<person name="Santiestevan E."/>
<person name="Nishi E."/>
<person name="Klagsbrun M."/>
</authorList>
<dbReference type="PubMed" id="10353604"/>
<dbReference type="DOI" id="10.1038/sj.onc.1202612"/>
</citation>
<scope>ALTERNATIVE SPLICING</scope>
<scope>FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PIK3R1</scope>
<scope>INTERACTION WITH NRG1 AND PIKR3R1</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1999" name="Oncogene" volume="18" first="2681" last="2689">
<title>Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.</title>
<authorList>
<person name="Harari D."/>
<person name="Tzahar E."/>
<person name="Romano J."/>
<person name="Shelly M."/>
<person name="Pierce J.H."/>
<person name="Andrews G.C."/>
<person name="Yarden Y."/>
</authorList>
<dbReference type="PubMed" id="10348342"/>
<dbReference type="DOI" id="10.1038/sj.onc.1202631"/>
</citation>
<scope>FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1 AND IN CELL PROLIFERATION</scope>
<scope>INTERACTION WITH NRG4</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="8641" last="8649">
<title>A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis.</title>
<authorList>
<person name="Kainulainen V."/>
<person name="Sundvall M."/>
<person name="Maatta J.A."/>
<person name="Santiestevan E."/>
<person name="Klagsbrun M."/>
<person name="Elenius K."/>
</authorList>
<dbReference type="PubMed" id="10722704"/>
<dbReference type="DOI" id="10.1074/jbc.275.12.8641"/>
</citation>
<scope>FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL AND IN PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1</scope>
<scope>ALTERNATIVE SPLICING</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="10379" last="10387">
<title>Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4.</title>
<authorList>
<person name="Rio C."/>
<person name="Buxbaum J.D."/>
<person name="Peschon J.J."/>
<person name="Corfas G."/>
</authorList>
<dbReference type="PubMed" id="10744726"/>
<dbReference type="DOI" id="10.1074/jbc.275.14.10379"/>
</citation>
<scope>PROTEOLYTIC PROCESSING</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="19803" last="19807">
<title>Ligand discrimination in signaling through an ErbB4 receptor homodimer.</title>
<authorList>
<person name="Sweeney C."/>
<person name="Lai C."/>
<person name="Riese D.J. II"/>
<person name="Diamonti A.J."/>
<person name="Cantley L.C."/>
<person name="Carraway K.L. III"/>
</authorList>
<dbReference type="PubMed" id="10867024"/>
<dbReference type="DOI" id="10.1074/jbc.C901015199"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1</scope>
<scope>INTERACTION WITH PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3</scope>
<scope>LIGAND-SPECIFIC AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2000" name="Proc. Natl. Acad. Sci. U.S.A." volume="97" first="3596" last="3601">
<title>The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses.</title>
<authorList>
<person name="Garcia R.A."/>
<person name="Vasudevan K."/>
<person name="Buonanno A."/>
</authorList>
<dbReference type="PubMed" id="10725395"/>
<dbReference type="DOI" id="10.1073/pnas.97.7.3596"/>
</citation>
<scope>INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2001" name="Biochem. Biophys. Res. Commun." volume="281" first="25" last="31">
<title>BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells.</title>
<authorList>
<person name="Egeblad M."/>
<person name="Mortensen O.H."/>
<person name="van Kempen L.C."/>
<person name="Jaattela M."/>
</authorList>
<dbReference type="PubMed" id="11178955"/>
<dbReference type="DOI" id="10.1006/bbrc.2001.4302"/>
</citation>
<scope>FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2001" name="Mol. Cell. Biol." volume="21" first="4265" last="4275">
<title>Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.</title>
<authorList>
<person name="Sartor C.I."/>
<person name="Zhou H."/>
<person name="Kozlowska E."/>
<person name="Guttridge K."/>
<person name="Kawata E."/>
<person name="Caskey L."/>
<person name="Harrelson J."/>
<person name="Hynes N."/>
<person name="Ethier S."/>
<person name="Calvo B."/>
<person name="Earp H.S. III"/>
</authorList>
<dbReference type="PubMed" id="11390655"/>
<dbReference type="DOI" id="10.1128/MCB.21.13.4265-4275.2001"/>
</citation>
<scope>MUTAGENESIS OF LYS-751</scope>
<scope>FUNCTION IN PROMOTING CELL DIFFERENTIATION AND INHIBITING CELL PROLIFERATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="33334" last="33341">
<title>WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus.</title>
<authorList>
<person name="Komuro A."/>
<person name="Nagai M."/>
<person name="Navin N.E."/>
<person name="Sudol M."/>
</authorList>
<dbReference type="PubMed" id="12807903"/>
<dbReference type="DOI" id="10.1074/jbc.M305597200"/>
</citation>
<scope>FUNCTION</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH YAP1</scope>
<scope>MUTAGENESIS OF TYR-1301</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2003" name="Mol. Cancer Res." volume="1" first="765" last="775">
<title>Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein.</title>
<authorList>
<person name="Li Y."/>
<person name="Yu W.-H."/>
<person name="Ren J."/>
<person name="Chen W."/>
<person name="Huang L."/>
<person name="Kharbanda S."/>
<person name="Loda M."/>
<person name="Kufe D."/>
</authorList>
<dbReference type="PubMed" id="12939402"/>
</citation>
<scope>INTERACTION WITH MUC1</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2004" name="J. Cell Biol." volume="167" first="469" last="478">
<title>The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.</title>
<authorList>
<person name="Williams C.C."/>
<person name="Allison J.G."/>
<person name="Vidal G.A."/>
<person name="Burow M.E."/>
<person name="Beckman B.S."/>
<person name="Marrero L."/>
<person name="Jones F.E."/>
</authorList>
<dbReference type="PubMed" id="15534001"/>
<dbReference type="DOI" id="10.1083/jcb.200403155"/>
</citation>
<scope>INTERACTION WITH STAT5A</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>FUNCTION IN NUCLEAR LOCALIZATION OF STAT5A; DNA-BINDING</scope>
<scope>MUTAGENESIS OF 681-LYS--ARG-684</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2005" name="Cancer Res." volume="65" first="6764" last="6772">
<title>WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function.</title>
<authorList>
<person name="Aqeilan R.I."/>
<person name="Donati V."/>
<person name="Palamarchuk A."/>
<person name="Trapasso F."/>
<person name="Kaou M."/>
<person name="Pekarsky Y."/>
<person name="Sudol M."/>
<person name="Croce C.M."/>
</authorList>
<dbReference type="PubMed" id="16061658"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-05-1150"/>
</citation>
<scope>INTERACTION WITH WWOX</scope>
<scope>DOMAIN</scope>
<scope>MUTAGENESIS OF TYR-1035 AND TYR-1301</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2005" name="J. Biol. Chem." volume="280" first="19777" last="19783">
<title>Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.</title>
<authorList>
<person name="Vidal G.A."/>
<person name="Naresh A."/>
<person name="Marrero L."/>
<person name="Jones F.E."/>
</authorList>
<dbReference type="PubMed" id="15746097"/>
<dbReference type="DOI" id="10.1074/jbc.M412457200"/>
</citation>
<scope>FUNCTION</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
<scope>MUTAGENESIS OF VAL-675</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2006" name="Cancer Res." volume="66" first="6412" last="6420">
<title>The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.</title>
<authorList>
<person name="Naresh A."/>
<person name="Long W."/>
<person name="Vidal G.A."/>
<person name="Wimley W.C."/>
<person name="Marrero L."/>
<person name="Sartor C.I."/>
<person name="Tovey S."/>
<person name="Cooke T.G."/>
<person name="Bartlett J.M."/>
<person name="Jones F.E."/>
</authorList>
<dbReference type="PubMed" id="16778220"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-05-2368"/>
</citation>
<scope>FUNCTION IN PROMOTING APOPTOSIS</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH BCL2</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="25373" last="25380">
<title>ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression.</title>
<authorList>
<person name="Linggi B."/>
<person name="Carpenter G."/>
</authorList>
<dbReference type="PubMed" id="16815842"/>
<dbReference type="DOI" id="10.1074/jbc.M603998200"/>
</citation>
<scope>INTERACTION WITH CBFA2T3</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2006" name="Mol. Biol. Cell" volume="17" first="67" last="79">
<title>Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.</title>
<authorList>
<person name="Maatta J.A."/>
<person name="Sundvall M."/>
<person name="Junttila T.T."/>
<person name="Peri L."/>
<person name="Laine V.J."/>
<person name="Isola J."/>
<person name="Egeblad M."/>
<person name="Elenius K."/>
</authorList>
<dbReference type="PubMed" id="16251361"/>
<dbReference type="DOI" id="10.1091/mbc.E05-05-0402"/>
</citation>
<scope>FUNCTION</scope>
<scope>PHOSPHORYLATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2006" name="Mol. Biol. Cell" volume="17" first="4118" last="4129">
<title>The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells.</title>
<authorList>
<person name="Muraoka-Cook R.S."/>
<person name="Sandahl M."/>
<person name="Husted C."/>
<person name="Hunter D."/>
<person name="Miraglia L."/>
<person name="Feng S.M."/>
<person name="Elenius K."/>
<person name="Earp H.S. III"/>
</authorList>
<dbReference type="PubMed" id="16837552"/>
<dbReference type="DOI" id="10.1091/mbc.E06-02-0101"/>
</citation>
<scope>FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH STAT5A</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2006" name="Oncol. Res." volume="16" first="179" last="193">
<title>Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.</title>
<authorList>
<person name="Pitfield S.E."/>
<person name="Bryant I."/>
<person name="Penington D.J."/>
<person name="Park G."/>
<person name="Riese D.J. II"/>
</authorList>
<dbReference type="PubMed" id="17120616"/>
</citation>
<scope>MUTAGENESIS OF GLN-646</scope>
<scope>PHOSPHORYLATION AT TYR-1056</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2007" name="Cancer Res." volume="67" first="6582" last="6590">
<title>HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.</title>
<authorList>
<person name="Strunk K.E."/>
<person name="Husted C."/>
<person name="Miraglia L.C."/>
<person name="Sandahl M."/>
<person name="Rearick W.A."/>
<person name="Hunter D.M."/>
<person name="Earp H.S. III"/>
<person name="Muraoka-Cook R.S."/>
</authorList>
<dbReference type="PubMed" id="17638867"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-06-4145"/>
</citation>
<scope>FUNCTION OF ERBB4 INTRACELLULAR DOMAIN</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN</scope>
<scope>MUTAGENESIS OF VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2007" name="Cell. Signal." volume="19" first="466" last="471">
<title>Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.</title>
<authorList>
<person name="Li Z."/>
<person name="Mei Y."/>
<person name="Liu X."/>
<person name="Zhou M."/>
</authorList>
<dbReference type="PubMed" id="16978839"/>
<dbReference type="DOI" id="10.1016/j.cellsig.2006.07.020"/>
</citation>
<scope>INTERACTION WITH ERBB2</scope>
<scope>MUTAGENESIS OF ASP-843</scope>
<scope>AUTOPHOSPHORYLATION IN TRANS</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2007" name="Oncogene" volume="26" first="6905" last="6914">
<title>Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.</title>
<authorList>
<person name="Sundvall M."/>
<person name="Peri L."/>
<person name="Maatta J.A."/>
<person name="Tvorogov D."/>
<person name="Paatero I."/>
<person name="Savisalo M."/>
<person name="Silvennoinen O."/>
<person name="Yarden Y."/>
<person name="Elenius K."/>
</authorList>
<dbReference type="PubMed" id="17486069"/>
<dbReference type="DOI" id="10.1038/sj.onc.1210501"/>
</citation>
<scope>FUNCTION OF E4ICD</scope>
<scope>PHOSPHORYLATION</scope>
<scope>SUBCELLULAR LOCATION OF E4ICD</scope>
<scope>MUTAGENESIS OF LYS-751</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2008" name="Chem. Biol." volume="15" first="808" last="817">
<title>System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.</title>
<authorList>
<person name="Kaushansky A."/>
<person name="Gordus A."/>
<person name="Budnik B.A."/>
<person name="Lane W.S."/>
<person name="Rush J."/>
<person name="MacBeath G."/>
</authorList>
<dbReference type="PubMed" id="18721752"/>
<dbReference type="DOI" id="10.1016/j.chembiol.2008.07.006"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162; TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284</scope>
<scope>INTERACTION WITH PIK3R1 AND STAT1</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2009" name="FASEB J." volume="23" first="1935" last="1945">
<title>Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells.</title>
<authorList>
<person name="Zeng F."/>
<person name="Xu J."/>
<person name="Harris R.C."/>
</authorList>
<dbReference type="PubMed" id="19193720"/>
<dbReference type="DOI" id="10.1096/fj.08-121947"/>
</citation>
<scope>INTERACTION WITH NEDD4</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>UBIQUITINATION OF E4ICD1</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2009" name="J. Biol. Chem." volume="284" first="5582" last="5591">
<title>Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.</title>
<authorList>
<person name="Tvorogov D."/>
<person name="Sundvall M."/>
<person name="Kurppa K."/>
<person name="Hollmen M."/>
<person name="Repo S."/>
<person name="Johnson M.S."/>
<person name="Elenius K."/>
</authorList>
<dbReference type="PubMed" id="19098003"/>
<dbReference type="DOI" id="10.1074/jbc.M805438200"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS</scope>
<scope>INTERACTION WITH ERBB2</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>PHOSPHORYLATION BY ERBB2</scope>
<scope>ENZYME REGULATION</scope>
<scope>MUTAGENESIS OF VAL-721; ALA-773; ARG-782; GLU-810; PRO-854; ASP-861; GLU-872 AND THR-926</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2009" name="Oncogene" volume="28" first="2948" last="2958">
<title>WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer.</title>
<authorList>
<person name="Li Y."/>
<person name="Zhou Z."/>
<person name="Alimandi M."/>
<person name="Chen C."/>
</authorList>
<dbReference type="PubMed" id="19561640"/>
<dbReference type="DOI" id="10.1038/onc.2009.162"/>
</citation>
<scope>INTERACTION WITH WWP1</scope>
<scope>MUTAGENESIS OF TYR-1056 AND TYR-1301</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2010" name="Mol. Cancer Res." volume="8" first="1388" last="1398">
<title>Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways.</title>
<authorList>
<person name="Gilmore-Hebert M."/>
<person name="Ramabhadran R."/>
<person name="Stern D.F."/>
</authorList>
<dbReference type="PubMed" id="20858735"/>
<dbReference type="DOI" id="10.1158/1541-7786.MCR-10-0042"/>
</citation>
<scope>INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1; U2SURP; ITCH; HNRPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND ARS2</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2011" name="Exp. Cell Res." volume="317" first="1476" last="1489">
<title>Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.</title>
<authorList>
<person name="Carrasco-Garcia E."/>
<person name="Saceda M."/>
<person name="Grasso S."/>
<person name="Rocamora-Reverte L."/>
<person name="Conde M."/>
<person name="Gomez-Martinez A."/>
<person name="Garcia-Morales P."/>
<person name="Ferragut J.A."/>
<person name="Martinez-Lacaci I."/>
</authorList>
<dbReference type="PubMed" id="21439954"/>
<dbReference type="DOI" id="10.1016/j.yexcr.2011.03.015"/>
</citation>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2003" name="Cell Cycle" volume="2" first="555" last="559">
<title>ErbB4 signaling during breast and neural development: novel genetic models reveal unique ErbB4 activities.</title>
<authorList>
<person name="Jones F.E."/>
<person name="Golding J.P."/>
<person name="Gassmann M."/>
</authorList>
<dbReference type="PubMed" id="14504474"/>
</citation>
<scope>REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2005" name="Histol. Histopathol." volume="20" first="1005" last="1015">
<title>The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.</title>
<authorList>
<person name="Zaczek A."/>
<person name="Brandt B."/>
<person name="Bielawski K.P."/>
</authorList>
<dbReference type="PubMed" id="15944951"/>
</citation>
<scope>REVIEW</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2008" name="J. Mammary Gland Biol. Neoplasia" volume="13" first="235" last="246">
<title>ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.</title>
<authorList>
<person name="Muraoka-Cook R.S."/>
<person name="Feng S.M."/>
<person name="Strunk K.E."/>
<person name="Earp H.S. III"/>
</authorList>
<dbReference type="PubMed" id="18437540"/>
<dbReference type="DOI" id="10.1007/s10911-008-9080-x"/>
</citation>
<scope>REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2008" name="J. Mammary Gland Biol. Neoplasia" volume="13" first="247" last="258">
<title>HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.</title>
<authorList>
<person name="Jones F.E."/>
</authorList>
<dbReference type="PubMed" id="18473151"/>
<dbReference type="DOI" id="10.1007/s10911-008-9076-6"/>
</citation>
<scope>REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2008" name="J. Mammary Gland Biol. Neoplasia" volume="13" first="259" last="268">
<title>Role of ErbB4 in breast cancer.</title>
<authorList>
<person name="Sundvall M."/>
<person name="Iljin K."/>
<person name="Kilpinen S."/>
<person name="Sara H."/>
<person name="Kallioniemi O.P."/>
<person name="Elenius K."/>
</authorList>
<dbReference type="PubMed" id="18454307"/>
<dbReference type="DOI" id="10.1007/s10911-008-9079-3"/>
</citation>
<scope>REVIEW ON LIGAND SPECIFICITY AND SIGNALING</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2010" name="Adv. Pharmacol." volume="59" first="31" last="51">
<title>Neuregulin-1/ErbB signaling and chronic heart failure.</title>
<authorList>
<person name="Xu Y."/>
<person name="Li X."/>
<person name="Liu X."/>
<person name="Zhou M."/>
</authorList>
<dbReference type="PubMed" id="20933198"/>
<dbReference type="DOI" id="10.1016/S1054-3589(10)59002-1"/>
</citation>
<scope>REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2011" name="Cell Cycle" volume="10" first="2647" last="2657">
<title>Function of ERBB4 is determined by alternative splicing.</title>
<authorList>
<person name="Veikkolainen V."/>
<person name="Vaparanta K."/>
<person name="Halkilahti K."/>
<person name="Iljin K."/>
<person name="Sundvall M."/>
<person name="Elenius K."/>
</authorList>
<dbReference type="PubMed" id="21811097"/>
<dbReference type="DOI" id="10.4161/cc.10.16.17194"/>
</citation>
<scope>REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE SPECIFICITY; SIGNALING AND ROLE IN DISEASE</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2005" name="Proc. Natl. Acad. Sci. U.S.A." volume="102" first="15024" last="15029">
<title>The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.</title>
<authorList>
<person name="Bouyain S."/>
<person name="Longo P.A."/>
<person name="Li S."/>
<person name="Ferguson K.M."/>
<person name="Leahy D.J."/>
</authorList>
<dbReference type="PubMed" id="16203964"/>
<dbReference type="DOI" id="10.1073/pnas.0507591102"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641</scope>
<scope>DISULFIDE BONDS</scope>
<scope>GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473; ASN-495 AND ASN-576</scope>
</reference>
<reference key="50">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="2773" last="2778">
<title>6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases.</title>
<authorList>
<person name="Wood E.R."/>
<person name="Shewchuk L.M."/>
<person name="Ellis B."/>
<person name="Brignola P."/>
<person name="Brashear R.L."/>
<person name="Caferro T.R."/>
<person name="Dickerson S.H."/>
<person name="Dickson H.D."/>
<person name="Donaldson K.H."/>
<person name="Gaul M."/>
<person name="Griffin R.J."/>
<person name="Hassell A.M."/>
<person name="Keith B."/>
<person name="Mullin R."/>
<person name="Petrov K.G."/>
<person name="Reno M.J."/>
<person name="Rusnak D.W."/>
<person name="Tadepalli S.M."/>
<person name="Ulrich J.C."/>
<person name="Wagner C.D."/>
<person name="Vanderwall D.E."/>
<person name="Waterson A.G."/>
<person name="Williams J.D."/>
<person name="White W.L."/>
<person name="Uehling D.E."/>
</authorList>
<dbReference type="PubMed" id="18287036"/>
<dbReference type="DOI" id="10.1073/pnas.0708281105"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH INHIBITOR</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>MUTAGENESIS OF LEU-710; MET-766; LEU-864 AND ILE-947</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2008" name="Structure" volume="16" first="460" last="467">
<title>Mechanism of activation and inhibition of the HER4/ErbB4 kinase.</title>
<authorList>
<person name="Qiu C."/>
<person name="Tarrant M.K."/>
<person name="Choi S.H."/>
<person name="Sathyamurthy A."/>
<person name="Bose R."/>
<person name="Banjade S."/>
<person name="Pal A."/>
<person name="Bornmann W.G."/>
<person name="Lemmon M.A."/>
<person name="Cole P.A."/>
<person name="Leahy D.J."/>
</authorList>
<dbReference type="PubMed" id="18334220"/>
<dbReference type="DOI" id="10.1016/j.str.2007.12.016"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN COMPLEX WITH LAPATINIB</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>SUBUNIT</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2013" name="Am. J. Hum. Genet." volume="93" first="900" last="905">
<title>ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.</title>
<authorList>
<person name="Takahashi Y."/>
<person name="Fukuda Y."/>
<person name="Yoshimura J."/>
<person name="Toyoda A."/>
<person name="Kurppa K."/>
<person name="Moritoyo H."/>
<person name="Belzil V.V."/>
<person name="Dion P.A."/>
<person name="Higasa K."/>
<person name="Doi K."/>
<person name="Ishiura H."/>
<person name="Mitsui J."/>
<person name="Date H."/>
<person name="Ahsan B."/>
<person name="Matsukawa T."/>
<person name="Ichikawa Y."/>
<person name="Moritoyo T."/>
<person name="Ikoma M."/>
<person name="Hashimoto T."/>
<person name="Kimura F."/>
<person name="Murayama S."/>
<person name="Onodera O."/>
<person name="Nishizawa M."/>
<person name="Yoshida M."/>
<person name="Atsuta N."/>
<person name="Sobue G."/>
<person name="Fifita J.A."/>
<person name="Williams K.L."/>
<person name="Blair I.P."/>
<person name="Nicholson G.A."/>
<person name="Gonzalez-Perez P."/>
<person name="Brown R.H. Jr."/>
<person name="Nomoto M."/>
<person name="Elenius K."/>
<person name="Rouleau G.A."/>
<person name="Fujiyama A."/>
<person name="Morishita S."/>
<person name="Goto J."/>
<person name="Tsuji S."/>
<person name="Nakamura R."/>
<person name="Watanabe H."/>
<person name="Izumi Y."/>
<person name="Kaji R."/>
<person name="Morita M."/>
<person name="Ogaki K."/>
<person name="Taniguchi A."/>
<person name="Aiba I."/>
<person name="Mizoguchi K."/>
<person name="Okamoto K."/>
<person name="Hasegawa K."/>
<person name="Aoki M."/>
<person name="Kawata A."/>
<person name="Nakano I."/>
<person name="Abe K."/>
<person name="Oda M."/>
<person name="Konagaya M."/>
<person name="Imai T."/>
<person name="Nakagawa M."/>
<person name="Fujita T."/>
<person name="Sasaki H."/>
<person name="Nishizawa M."/>
</authorList>
<dbReference type="PubMed" id="24119685"/>
<dbReference type="DOI" id="10.1016/j.ajhg.2013.09.008"/>
</citation>
<scope>VARIANTS ALS19 GLN-927 AND TRP-1275</scope>
<scope>CHARACTERIZATION OF VARIANTS ASL19 GLN-927 AND TRP-1275</scope>
</reference>
<comment type="function">
<text evidence="11 12 13 14 17 18 19 20 22 23 26 27 29 33 34 38 41 46 48 49 50 52">Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis.</text>
</comment>
<comment type="catalytic activity">
<text evidence="10 35 36 38 48">ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="18 36 38 42 48">Binding of a cognate ligand leads to dimerization and activation by autophosphorylation on tyrosine residues. In vitro kinase activity is increased by Mg(2+). Inhibited by PD153035, lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS.</text>
</comment>
<comment type="subunit">
<text evidence="7 11 12 13 15 17 20 21 22 24 27 28 29 30 35 36 37 38 39 40 41 44 45 47 48 49 50 51 53 54">Monomer in the absence of bound ligand. Homodimer or heterodimer with another ERBB family member upon ligand binding, thus forming heterotetramers. Interacts with EGFR and ERBB2. Interacts with CBFA2T3 (By similarity). Interacts with DLG2 (via its PDZ domain), DLG3 (via its PDZ domain), DLG4 (via its PDZ domain) and SNTB2 (via its PDZ domain). Interacts with MUC1. Interacts (via its PPxy motifs) with WWOX. Interacts (via the PPxY motif 3 of isoform JM-A CYT-2) with YAP1 (via the WW domain 1 of isoform 1). Interacts (isoform JM-A CYT-1 and isoform JM-B CYT-1) with WWP1. Interacts (via its intracellular domain) with TRIM28. Interacts (via the intracellular domains of both CYT-1 and CYT-2 isoforms) with KAP1; the interaction does not phosphorylate KAP1 but represses ERBB4-mediated transcriptional activity. Interacts with PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH, HNRPU, AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 AND ARS2. Interacts (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-1) with PIK3R1. Interacts with SHC1. Interacts with GRB2. Interacts (soluble intracellular domain) with STAT5A. Interacts (soluble intracellular domain) with BCL2. Interacts (phosphorylated) with STAT1.</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-80371"/>
<interactant intactId="EBI-1102694">
<id>P42684</id>
<label>ABL2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-80371"/>
<interactant intactId="EBI-80389">
<id>P78352</id>
<label>DLG4</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-80371"/>
<interactant intactId="EBI-297353">
<id>P00533</id>
<label>EGFR</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-80371"/>
<interactant intactId="EBI-641062">
<id>P04626</id>
<label>ERBB2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-80371"/>
<interactant intactId="EBI-720706">
<id>P21860</id>
<label>ERBB3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-80371"/>
<interactant intactId="EBI-352572">
<id>P08238</id>
<label>HSP90AB1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-80371"/>
<interactant intactId="EBI-78835">
<id>P29353</id>
<label>SHC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-80371"/>
<interactant intactId="EBI-1044059">
<id>P46937</id>
<label>YAP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="11 20 22 26 27 29 33 34 39 41 46 52">Cell membrane</location>
<topology evidence="11 20 22 26 27 29 33 34 39 41 46 52">Single-pass type I membrane protein</topology>
</subcellularLocation>
<text>In response to NRG1 treatment, the activated receptor is internalized.</text>
</comment>
<comment type="subcellular location">
<molecule>ERBB4 intracellular domain</molecule>
<subcellularLocation>
<location evidence="33">Nucleus</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="33">Mitochondrion</location>
</subcellularLocation>
<text>Following proteolytical processing E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus.</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>Q15303-1</id>
<name>JM-A CYT-1</name>
<sequence type="displayed"/>
<text>Proteolytical processing generates E4ICD1 (s80Cyt1).</text>
</isoform>
<isoform>
<id>Q15303-2</id>
<name>JM-B CYT-1</name>
<sequence type="described" ref="VSP_002895"/>
</isoform>
<isoform>
<id>Q15303-3</id>
<name>JM-A CYT-2</name>
<sequence type="described" ref="VSP_022148"/>
<text>Proteolytical processing generates E4ICD2 (s80Cyt2).</text>
</isoform>
<isoform>
<id>Q15303-4</id>
<name>JM-B CYT-2</name>
<sequence type="described" ref="VSP_002895 VSP_022148"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="12 46 52">Expressed at highest levels in brain, heart, kidney, in addition to skeletal muscle, parathyroid, cerebellum, pituitary, spleen, testis and breast. Lower levels in thymus, lung, salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are expressed in cerebellum, but only the isoform JM-B is expressed in the heart.</text>
</comment>
<comment type="PTM">
<text evidence="16 20 23 29 34 52">Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. Proteolytic processing in response to ligand or 12-O-tetradecanoylphorbol-13-acetate stimulation results in the production of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 kDa fragments (m80HER4), which are further processed by a presenilin-dependent gamma-secretase to release a cytoplasmic intracellular domain (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 are more readily degraded by the proteasome than fragments of isoform JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not processed by ADAM17, precluding further processing by gamma-secretase.</text>
</comment>
<comment type="PTM">
<text evidence="26 31 33 37 38 48 50">Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Ligands trigger phosphorylation at specific tyrosine residues, thereby creating binding sites for scaffold proteins and effectors. Constitutively phosphorylated at a basal level when overexpressed in heterologous systems; ligand binding leads to increased phosphorylation. Phosphorylation at Tyr-1035 is important for interaction with STAT1. Phosphorylation at Tyr-1056 is important for interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively phosphorylated on tyrosine residues in a ligand-independent manner. E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues.</text>
</comment>
<comment type="PTM">
<text evidence="34 39">Ubiquitinated. During mitosis, the ERBB4 intracellular domain is ubiquitinated by the APC/C complex and targeted to proteasomal degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is ubiquitinated, and this involves NEDD4.</text>
</comment>
<comment type="disease" evidence="43">
<disease id="DI-03940">
<name>Amyotrophic lateral sclerosis 19</name>
<acronym>ALS19</acronym>
<description>A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.</description>
<dbReference type="MIM" id="615515"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="9">Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.</text>
</comment>
<comment type="caution">
<text evidence="58">Conflicting reports about the role of ERBB4 in mediating apoptosis, differentiation, or tumor cell proliferation may be explained by the opposite functions of the different isoforms and their intracellular fragments, and by the formation of heterodimers with other EGF receptor family members (PubMed:18454307 and PubMed:21811097). Thus, heterodimer formation of a kinase-dead ERBB4 mutant with ERBB2 is sufficient for the activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 (PubMed:19098003).</text>
</comment>
<dbReference type="EC" id="2.7.10.1"/>
<dbReference type="EMBL" id="L07868">
<property type="protein sequence ID" value="AAB59446.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC112199">
<property type="protein sequence ID" value="AAI12200.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC143741">
<property type="protein sequence ID" value="AAI43742.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC143747">
<property type="protein sequence ID" value="AAI43748.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC143749">
<property type="protein sequence ID" value="AAI43750.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AB209697">
<property type="protein sequence ID" value="BAD92934.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS2394.1">
<molecule id="Q15303-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS42811.1">
<molecule id="Q15303-3"/>
</dbReference>
<dbReference type="PIR" id="A47253">
<property type="entry name" value="A47253"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001036064.1">
<molecule id="Q15303-3"/>
<property type="nucleotide sequence ID" value="NM_001042599.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_005226.1">
<molecule id="Q15303-1"/>
<property type="nucleotide sequence ID" value="NM_005235.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_005246433.1">
<molecule id="Q15303-2"/>
<property type="nucleotide sequence ID" value="XM_005246376.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_005246434.1">
<molecule id="Q15303-4"/>
<property type="nucleotide sequence ID" value="XM_005246377.2"/>
</dbReference>
<dbReference type="UniGene" id="Hs.390729"/>
<dbReference type="PDB" id="2AHX">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A/B=26-641"/>
</dbReference>
<dbReference type="PDB" id="2L2T">
<property type="method" value="NMR"/>
<property type="chains" value="A/B=642-685"/>
</dbReference>
<dbReference type="PDB" id="2LCX">
<property type="method" value="NMR"/>
<property type="chains" value="A/B=642-685"/>
</dbReference>
<dbReference type="PDB" id="2R4B">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A/B=690-999"/>
</dbReference>
<dbReference type="PDB" id="3BBT">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="B/D=702-1029"/>
</dbReference>
<dbReference type="PDB" id="3BBW">
<property type="method" value="X-ray"/>
<property type="resolution" value="4.00"/>
<property type="chains" value="A/B=702-1029"/>
</dbReference>
<dbReference type="PDB" id="3BCE">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/B/C=702-1029"/>
</dbReference>
<dbReference type="PDB" id="3U2P">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.57"/>
<property type="chains" value="A=26-522"/>
</dbReference>
<dbReference type="PDB" id="3U7U">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.03"/>
<property type="chains" value="A/B/C/D/E/F=26-640"/>
</dbReference>
<dbReference type="PDB" id="3U9U">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.42"/>
<property type="chains" value="E/F=26-650"/>
</dbReference>
<dbReference type="PDBsum" id="2AHX"/>
<dbReference type="PDBsum" id="2L2T"/>
<dbReference type="PDBsum" id="2LCX"/>
<dbReference type="PDBsum" id="2R4B"/>
<dbReference type="PDBsum" id="3BBT"/>
<dbReference type="PDBsum" id="3BBW"/>
<dbReference type="PDBsum" id="3BCE"/>
<dbReference type="PDBsum" id="3U2P"/>
<dbReference type="PDBsum" id="3U7U"/>
<dbReference type="PDBsum" id="3U9U"/>
<dbReference type="ProteinModelPortal" id="Q15303"/>
<dbReference type="SMR" id="Q15303"/>
<dbReference type="BioGrid" id="108378">
<property type="interactions" value="49"/>
</dbReference>
<dbReference type="DIP" id="DIP-29650N"/>
<dbReference type="IntAct" id="Q15303">
<property type="interactions" value="26"/>
</dbReference>
<dbReference type="MINT" id="MINT-125091"/>
<dbReference type="STRING" id="9606.ENSP00000342235"/>
<dbReference type="BindingDB" id="Q15303"/>
<dbReference type="ChEMBL" id="CHEMBL3009"/>
<dbReference type="DrugBank" id="DB08916">
<property type="generic name" value="Afatinib"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1799"/>
<dbReference type="TCDB" id="1.A.87.2.6">
<property type="family name" value="the mechanosensitive calcium channel (mca) family"/>
</dbReference>
<dbReference type="iPTMnet" id="Q15303"/>
<dbReference type="PhosphoSitePlus" id="Q15303"/>
<dbReference type="BioMuta" id="ERBB4"/>
<dbReference type="DMDM" id="3913590"/>
<dbReference type="MaxQB" id="Q15303"/>
<dbReference type="PaxDb" id="Q15303"/>
<dbReference type="PeptideAtlas" id="Q15303"/>
<dbReference type="PRIDE" id="Q15303"/>
<dbReference type="DNASU" id="2066"/>
<dbReference type="Ensembl" id="ENST00000342788">
<molecule id="Q15303-1"/>
<property type="protein sequence ID" value="ENSP00000342235"/>
<property type="gene ID" value="ENSG00000178568"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000436443">
<molecule id="Q15303-3"/>
<property type="protein sequence ID" value="ENSP00000403204"/>
<property type="gene ID" value="ENSG00000178568"/>
</dbReference>
<dbReference type="GeneID" id="2066"/>
<dbReference type="KEGG" id="hsa:2066"/>
<dbReference type="UCSC" id="uc002veg.2">
<molecule id="Q15303-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="2066"/>
<dbReference type="DisGeNET" id="2066"/>
<dbReference type="GeneCards" id="ERBB4"/>
<dbReference type="HGNC" id="HGNC:3432">
<property type="gene designation" value="ERBB4"/>
</dbReference>
<dbReference type="HPA" id="CAB000276"/>
<dbReference type="HPA" id="CAB025522"/>
<dbReference type="HPA" id="HPA012016"/>
<dbReference type="MalaCards" id="ERBB4"/>
<dbReference type="MIM" id="600543">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="615515">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_Q15303"/>
<dbReference type="OpenTargets" id="ENSG00000178568"/>
<dbReference type="Orphanet" id="803">
<property type="disease" value="Amyotrophic lateral sclerosis"/>
</dbReference>
<dbReference type="PharmGKB" id="PA27847"/>
<dbReference type="eggNOG" id="KOG1025">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="ENOG410XNSR">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000118799"/>
<dbReference type="HOGENOM" id="HOG000230982"/>
<dbReference type="HOVERGEN" id="HBG000490"/>
<dbReference type="InParanoid" id="Q15303"/>
<dbReference type="KO" id="K05085"/>
<dbReference type="OMA" id="RTRIDSN"/>
<dbReference type="OrthoDB" id="EOG091G00EY"/>
<dbReference type="PhylomeDB" id="Q15303"/>
<dbReference type="TreeFam" id="TF106002"/>
<dbReference type="BRENDA" id="2.7.10.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1227986">
<property type="pathway name" value="Signaling by ERBB2"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1236394">
<property type="pathway name" value="Signaling by ERBB4"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1250196">
<property type="pathway name" value="SHC1 events in ERBB2 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1250342">
<property type="pathway name" value="PI3K events in ERBB4 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1250347">
<property type="pathway name" value="SHC1 events in ERBB4 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1251985">
<property type="pathway name" value="Nuclear signaling by ERBB4"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1253288">
<property type="pathway name" value="Downregulation of ERBB4 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1257604">
<property type="pathway name" value="PIP3 activates AKT signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1963640">
<property type="pathway name" value="GRB2 events in ERBB2 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1963642">
<property type="pathway name" value="PI3K events in ERBB2 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2219530">
<property type="pathway name" value="Constitutive Signaling by Aberrant PI3K in Cancer"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5673001">
<property type="pathway name" value="RAF/MAP kinase cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6785631">
<property type="pathway name" value="ERBB2 Regulates Cell Motility"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6811558">
<property type="pathway name" value="PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8847993">
<property type="pathway name" value="ERBB2 Activates PTK6 Signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8863795">
<property type="pathway name" value="Downregulation of ERBB2 signaling"/>
</dbReference>
<dbReference type="SignaLink" id="Q15303"/>
<dbReference type="SIGNOR" id="Q15303"/>
<dbReference type="ChiTaRS" id="ERBB4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="Q15303"/>
<dbReference type="GeneWiki" id="ERBB4"/>
<dbReference type="GenomeRNAi" id="2066"/>
<dbReference type="PMAP-CutDB" id="Q15303"/>
<dbReference type="PRO" id="PR:Q15303"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 2"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000178568"/>
<dbReference type="CleanEx" id="HS_ERBB4"/>
<dbReference type="ExpressionAtlas" id="Q15303">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="Q15303">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0016323">
<property type="term" value="C:basolateral plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005576">
<property type="term" value="C:extracellular region"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0016021">
<property type="term" value="C:integral component of membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0005759">
<property type="term" value="C:mitochondrial matrix"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005739">
<property type="term" value="C:mitochondrion"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043235">
<property type="term" value="C:receptor complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0005154">
<property type="term" value="F:epidermal growth factor receptor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046934">
<property type="term" value="F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0042803">
<property type="term" value="F:protein homodimerization activity"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004713">
<property type="term" value="F:protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005088">
<property type="term" value="F:Ras guanyl-nucleotide exchange factor activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0004716">
<property type="term" value="F:signal transducer, downstream of receptor, with protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0044212">
<property type="term" value="F:transcription regulatory region DNA binding"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004714">
<property type="term" value="F:transmembrane receptor protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0061026">
<property type="term" value="P:cardiac muscle tissue regeneration"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045165">
<property type="term" value="P:cell fate commitment"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0016477">
<property type="term" value="P:cell migration"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008283">
<property type="term" value="P:cell proliferation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0071364">
<property type="term" value="P:cellular response to epidermal growth factor stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0021551">
<property type="term" value="P:central nervous system morphogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0009880">
<property type="term" value="P:embryonic pattern specification"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0038128">
<property type="term" value="P:ERBB2 signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0007507">
<property type="term" value="P:heart development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007595">
<property type="term" value="P:lactation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0060749">
<property type="term" value="P:mammary gland alveolus development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0060644">
<property type="term" value="P:mammary gland epithelial cell differentiation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000165">
<property type="term" value="P:MAPK cascade"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043653">
<property type="term" value="P:mitochondrial fragmentation involved in apoptotic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043066">
<property type="term" value="P:negative regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008285">
<property type="term" value="P:negative regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1901185">
<property type="term" value="P:negative regulation of ERBB signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:2001223">
<property type="term" value="P:negative regulation of neuron migration"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007399">
<property type="term" value="P:nervous system development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001755">
<property type="term" value="P:neural crest cell migration"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0021889">
<property type="term" value="P:olfactory bulb interneuron differentiation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0038083">
<property type="term" value="P:peptidyl-tyrosine autophosphorylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0018108">
<property type="term" value="P:peptidyl-tyrosine phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048015">
<property type="term" value="P:phosphatidylinositol-mediated signaling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043065">
<property type="term" value="P:positive regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0060045">
<property type="term" value="P:positive regulation of cardiac muscle cell proliferation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070374">
<property type="term" value="P:positive regulation of ERK1 and ERK2 cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043552">
<property type="term" value="P:positive regulation of phosphatidylinositol 3-kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0014068">
<property type="term" value="P:positive regulation of phosphatidylinositol 3-kinase signaling"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:2000010">
<property type="term" value="P:positive regulation of protein localization to cell surface"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001934">
<property type="term" value="P:positive regulation of protein phosphorylation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000366">
<property type="term" value="P:positive regulation of STAT protein import into nucleus"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045893">
<property type="term" value="P:positive regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042523">
<property type="term" value="P:positive regulation of tyrosine phosphorylation of Stat5 protein"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046777">
<property type="term" value="P:protein autophosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030334">
<property type="term" value="P:regulation of cell migration"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000145">
<property type="term" value="P:regulation of cell motility"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0014066">
<property type="term" value="P:regulation of phosphatidylinositol 3-kinase signaling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0007165">
<property type="term" value="P:signal transduction"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006351">
<property type="term" value="P:transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0007169">
<property type="term" value="P:transmembrane receptor protein tyrosine kinase signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="Gene3D" id="3.80.20.20">
<property type="match status" value="3"/>
</dbReference>
<dbReference type="InterPro" id="IPR006211">
<property type="entry name" value="Furin-like_Cys-rich_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR006212">
<property type="entry name" value="Furin_repeat"/>
</dbReference>
<dbReference type="InterPro" id="IPR032778">
<property type="entry name" value="GF_recep_IV"/>
</dbReference>
<dbReference type="InterPro" id="IPR009030">
<property type="entry name" value="Growth_fac_rcpt_"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR032675">
<property type="entry name" value="L_dom-like"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR000494">
<property type="entry name" value="Rcpt_L-dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR001245">
<property type="entry name" value="Ser-Thr/Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR008266">
<property type="entry name" value="Tyr_kinase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR020635">
<property type="entry name" value="Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR016245">
<property type="entry name" value="Tyr_kinase_EGF/ERB/XmrK_rcpt"/>
</dbReference>
<dbReference type="Pfam" id="PF00757">
<property type="entry name" value="Furin-like"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF14843">
<property type="entry name" value="GF_recep_IV"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07714">
<property type="entry name" value="Pkinase_Tyr"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF01030">
<property type="entry name" value="Recep_L_domain"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PIRSF" id="PIRSF000619">
<property type="entry name" value="TyrPK_EGF-R"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00109">
<property type="entry name" value="TYRKINASE"/>
</dbReference>
<dbReference type="SMART" id="SM00261">
<property type="entry name" value="FU"/>
<property type="match status" value="5"/>
</dbReference>
<dbReference type="SMART" id="SM00219">
<property type="entry name" value="TyrKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF52058">
<property type="entry name" value="SSF52058"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF57184">
<property type="entry name" value="SSF57184"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00109">
<property type="entry name" value="PROTEIN_KINASE_TYR"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0010">Activator</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0036">Amyotrophic lateral sclerosis</keyword>
<keyword id="KW-0053">Apoptosis</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0217">Developmental protein</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0421">Lactation</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0496">Mitochondrion</keyword>
<keyword id="KW-0523">Neurodegeneration</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0804">Transcription</keyword>
<keyword id="KW-0805">Transcription regulation</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<keyword id="KW-0829">Tyrosine-protein kinase</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="signal peptide" evidence="8">
<location>
<begin position="1"/>
<end position="25"/>
</location>
</feature>
<feature type="chain" description="Receptor tyrosine-protein kinase erbB-4" id="PRO_0000016674">
<location>
<begin position="26"/>
<end position="1308"/>
</location>
</feature>
<feature type="chain" description="ERBB4 intracellular domain" id="PRO_0000396797" evidence="7">
<location>
<begin position="676"/>
<end position="1308"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="8">
<location>
<begin position="26"/>
<end position="651"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="8">
<location>
<begin position="652"/>
<end position="675"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="8">
<location>
<begin position="676"/>
<end position="1308"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="9">
<location>
<begin position="718"/>
<end position="985"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="9">
<location>
<begin position="724"/>
<end position="732"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="9">
<location>
<begin position="797"/>
<end position="799"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="9">
<location>
<begin position="843"/>
<end position="848"/>
</location>
</feature>
<feature type="short sequence motif" description="Nuclear localization signal">
<location>
<begin position="676"/>
<end position="684"/>
</location>
</feature>
<feature type="short sequence motif" description="PPxY motif 1">
<location>
<begin position="1032"/>
<end position="1035"/>
</location>
</feature>
<feature type="short sequence motif" description="PPxY motif 2">
<location>
<begin position="1053"/>
<end position="1056"/>
</location>
</feature>
<feature type="short sequence motif" description="PPxY motif 3">
<location>
<begin position="1298"/>
<end position="1301"/>
</location>
</feature>
<feature type="short sequence motif" description="PDZ-binding">
<location>
<begin position="1306"/>
<end position="1308"/>
</location>
</feature>
<feature type="compositionally biased region" description="Cys-rich">
<location>
<begin position="186"/>
<end position="334"/>
</location>
</feature>
<feature type="compositionally biased region" description="Cys-rich">
<location>
<begin position="496"/>
<end position="633"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="9 10">
<location>
<position position="843"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="9">
<location>
<position position="751"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37">
<location>
<position position="875"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37">
<location>
<position position="1035"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="31 37 48">
<location>
<position position="1056"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37">
<location>
<position position="1150"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37">
<location>
<position position="1162"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37 48">
<location>
<position position="1188"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37">
<location>
<position position="1202"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37 48">
<location>
<position position="1242"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37">
<location>
<position position="1258"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="37">
<location>
<position position="1284"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="25">
<location>
<position position="138"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="25">
<location>
<position position="174"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="8">
<location>
<position position="181"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="25">
<location>
<position position="253"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="25">
<location>
<position position="358"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="25">
<location>
<position position="410"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="25">
<location>
<position position="473"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="25">
<location>
<position position="495"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="8">
<location>
<position position="548"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="25">
<location>
<position position="576"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="8">
<location>
<position position="620"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="29"/>
<end position="56"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="156"/>
<end position="186"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="189"/>
<end position="197"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="193"/>
<end position="205"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="213"/>
<end position="221"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="217"/>
<end position="229"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="230"/>
<end position="238"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="234"/>
<end position="246"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="249"/>
<end position="258"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="262"/>
<end position="289"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="293"/>
<end position="304"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="308"/>
<end position="323"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="326"/>
<end position="330"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="503"/>
<end position="512"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="507"/>
<end position="520"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="523"/>
<end position="532"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="536"/>
<end position="552"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="555"/>
<end position="569"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="559"/>
<end position="577"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="580"/>
<end position="589"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="593"/>
<end position="614"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="617"/>
<end position="625"/>
</location>
</feature>
<feature type="disulfide bond" evidence="25">
<location>
<begin position="621"/>
<end position="633"/>
</location>
</feature>
<feature type="splice variant" description="In isoform JM-B CYT-1 and isoform JM-B CYT-2." id="VSP_002895" evidence="55 56">
<original>NGPTSHDCIYYPWTGHSTLPQHA</original>
<variation>IGSSIEDCIGLMD</variation>
<location>
<begin position="626"/>
<end position="648"/>
</location>
</feature>
<feature type="splice variant" description="In isoform JM-A CYT-2 and isoform JM-B CYT-2." id="VSP_022148" evidence="55 57">
<location>
<begin position="1046"/>
<end position="1061"/>
</location>
</feature>
<feature type="sequence variant" description="In a colorectal adenocarcinoma sample; somatic mutation." id="VAR_042113" evidence="32">
<original>T</original>
<variation>I</variation>
<location>
<position position="140"/>
</location>
</feature>
<feature type="sequence variant" description="In a lung squamous cell carcinoma sample; somatic mutation." id="VAR_042114" evidence="32">
<original>S</original>
<variation>Y</variation>
<location>
<position position="303"/>
</location>
</feature>
<feature type="sequence variant" description="In ALS19; reduces autophosphorylation upon NRG1 stimulation; dbSNP:rs397514262." id="VAR_070810" evidence="43">
<original>R</original>
<variation>Q</variation>
<location>
<position position="927"/>
</location>
</feature>
<feature type="sequence variant" description="In ALS19; reduces autophosphorylation upon NRG1 stimulation; dbSNP:rs397514263." id="VAR_070811" evidence="43">
<original>R</original>
<variation>W</variation>
<location>
<position position="1275"/>
</location>
</feature>
<feature type="mutagenesis site" description="Constitutively activated kinase." evidence="31">
<original>Q</original>
<variation>C</variation>
<location>
<position position="646"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes proteolytic processing and nuclear localization." evidence="23 34">
<original>V</original>
<variation>A</variation>
<location>
<position position="675"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes nuclear localization of the ERBB4 intracellular domain." evidence="22">
<original>KKKR</original>
<variation>EIMG</variation>
<location>
<begin position="681"/>
<end position="684"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced autophosphorylation." evidence="35">
<original>L</original>
<variation>N</variation>
<location>
<position position="710"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on kinase activity." evidence="38">
<original>V</original>
<variation>I</variation>
<location>
<position position="721"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes kinase activity. Abolishes phosphorylation, proteolytic processing and nuclear localization." evidence="19 33 34">
<original>K</original>
<variation>R</variation>
<location>
<position position="751"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced autophosphorylation." evidence="35">
<original>M</original>
<variation>R</variation>
<location>
<position position="766"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on kinase activity." evidence="38">
<original>A</original>
<variation>S</variation>
<location>
<position position="773"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on kinase activity." evidence="38">
<original>R</original>
<variation>Q</variation>
<location>
<position position="782"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on kinase activity." evidence="38">
<original>E</original>
<variation>K</variation>
<location>
<position position="810"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of kinase activity." evidence="30">
<original>D</original>
<variation>N</variation>
<location>
<position position="843"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on kinase activity." evidence="38">
<original>P</original>
<variation>Q</variation>
<location>
<position position="854"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of kinase activity." evidence="38">
<original>D</original>
<variation>Y</variation>
<location>
<position position="861"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced autophosphorylation." evidence="35">
<original>L</original>
<variation>R</variation>
<location>
<position position="864"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on kinase activity." evidence="38">
<original>E</original>
<variation>K</variation>
<location>
<position position="872"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on kinase activity." evidence="38">
<original>T</original>
<variation>M</variation>
<location>
<position position="926"/>
</location>
</feature>
<feature type="mutagenesis site" description="Constitutively autophosphorylated." evidence="35">
<original>I</original>
<variation>R</variation>
<location>
<position position="947"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes APC/C-mediated degradation; when associated with A-995 and A-1000." evidence="34">
<original>R</original>
<variation>A</variation>
<location>
<position position="992"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes APC/C-mediated degradation; when associated with A-992 and A-1000." evidence="34">
<original>L</original>
<variation>A</variation>
<location>
<position position="995"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes APC/C-mediated degradation; when associated with A-992 and A-995." evidence="34">
<original>D</original>
<variation>A</variation>
<location>
<position position="1000"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on interaction with WWOX. Abolishes interaction with WWOX; when associated with A-1301." evidence="24">
<original>Y</original>
<variation>A</variation>
<location>
<position position="1035"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with NEDD4 and impairs ubiquitination. Promotes nuclear translocation of ERBB4 intracellular domain E4ICD1." evidence="40">
<original>Y</original>
<variation>A</variation>
<location>
<position position="1056"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with WWP1; when associated with F-1301." evidence="40">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1056"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with NEDD4 and impairs ubiquitination." evidence="20 24 40">
<original>Y</original>
<variation>A</variation>
<location>
<position position="1301"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on interaction with WWOX. Abolishes interaction with WWOX; when associated with A-1035. Loss of interaction with YAP1 and stimulation of transcription." evidence="20 24 40">
<original>Y</original>
<variation>A</variation>
<location>
<position position="1301"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with WWP1; when associated with F-1056." evidence="20 24 40">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1301"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="28"/>
<end position="30"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="38"/>
<end position="41"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="42"/>
<end position="53"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="57"/>
<end position="61"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="63"/>
<end position="67"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="75"/>
<end position="79"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="82"/>
<end position="85"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="87"/>
<end position="91"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="95"/>
<end position="98"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="112"/>
<end position="114"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="115"/>
<end position="120"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="125"/>
<end position="128"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="133"/>
<end position="135"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="144"/>
<end position="150"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="158"/>
<end position="160"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="163"/>
<end position="165"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="173"/>
<end position="175"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="176"/>
<end position="178"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="191"/>
<end position="193"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="197"/>
<end position="201"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="202"/>
<end position="204"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="221"/>
<end position="225"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="226"/>
<end position="228"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="234"/>
<end position="242"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="245"/>
<end position="254"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="257"/>
<end position="261"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="265"/>
<end position="269"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="270"/>
<end position="273"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="274"/>
<end position="277"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="283"/>
<end position="285"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="288"/>
<end position="292"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="298"/>
<end position="300"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="303"/>
<end position="307"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="312"/>
<end position="317"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="320"/>
<end position="325"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="327"/>
<end position="329"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="333"/>
<end position="335"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="340"/>
<end position="342"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="350"/>
<end position="352"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="353"/>
<end position="356"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="360"/>
<end position="364"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="366"/>
<end position="368"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="370"/>
<end position="374"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="377"/>
<end position="379"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="386"/>
<end position="394"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="397"/>
<end position="400"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="402"/>
<end position="405"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="415"/>
<end position="417"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="432"/>
<end position="438"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="455"/>
<end position="461"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="469"/>
<end position="471"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="474"/>
<end position="476"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="479"/>
<end position="482"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="485"/>
<end position="487"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="489"/>
<end position="491"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="493"/>
<end position="497"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="498"/>
<end position="500"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="512"/>
<end position="516"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="519"/>
<end position="528"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="531"/>
<end position="534"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="537"/>
<end position="543"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="545"/>
<end position="548"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="551"/>
<end position="554"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="568"/>
<end position="573"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="576"/>
<end position="585"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="588"/>
<end position="592"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="595"/>
<end position="608"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="612"/>
<end position="616"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="625"/>
<end position="629"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="651"/>
<end position="676"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="715"/>
<end position="717"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="718"/>
<end position="729"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="731"/>
<end position="737"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="740"/>
<end position="743"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="746"/>
<end position="752"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="762"/>
<end position="773"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="778"/>
<end position="780"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="783"/>
<end position="787"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="789"/>
<end position="791"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="793"/>
<end position="797"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="804"/>
<end position="810"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="812"/>
<end position="814"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="817"/>
<end position="836"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="846"/>
<end position="848"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="849"/>
<end position="853"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="856"/>
<end position="859"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="864"/>
<end position="869"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="884"/>
<end position="886"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="889"/>
<end position="893"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="899"/>
<end position="914"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="920"/>
<end position="923"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="926"/>
<end position="928"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="929"/>
<end position="934"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="947"/>
<end position="955"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="961"/>
<end position="963"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="967"/>
<end position="977"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="981"/>
<end position="983"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2AHX"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2L2T"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2R4B"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3BBT"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3U2P"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3U7U"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000250"/>
<evidence key="8" type="ECO:0000255"/>
<evidence key="9" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10028"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10348342"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10353604"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10358079"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10722704"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10725395"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10744726"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10867024"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11178955"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11390655"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12807903"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12939402"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15534001"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15746097"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16061658"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16203964"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16251361"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16778220"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16815842"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16837552"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16978839"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17120616"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17486069"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17638867"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18287036"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18334220"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18721752"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19098003"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19193720"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19561640"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20858735"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21439954"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24119685"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7689552"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7902537"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8383326"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8570211"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8617750"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9135143"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9168115"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9275162"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9334263"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9419975"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9516479"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="9334263"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000303">
<source ref="4"/>
</evidence>
<evidence key="58" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="19098003"/>
</source>
</evidence>
<sequence length="1308" mass="146808" checksum="5E4AE80985D88761" modified="1996-11-01" version="1" precursor="true">
MKPATGLWVWVSLLVAAGTVQPSDSQSVCAGTENKLSSLSDLEQQYRALRKYYENCEVVM
GNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAIF
LNYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVST
NGSSGCGRCHKSCTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSG
PKDTDCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVD
SSSCVRACPSSKMEVEENGIKMCKPCTDICPKACDGIGTGSLMSAQTVDSSNIDKFINCT
KINGNLIFLVTGIHGDPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPPNMTDFSVFSNL
VTIGGRVLYSGLSLLILKQQGITSLQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFST
INQRIVIRDNRKAENCTAEGMVCNHLCSSDGCWGPGPDQCLSCRRFSRGRICIESCNLYD
GEFREFENGSICVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDGPNCVEKCPDGLQGA
NSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGG
LFILVIVGLTFAVYVRRKSIKKKRALRRFLETELVEPLTPSGTAPNQAQLRILKETELKR
VKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGPKANVEFMDEALIMASMDHPHL
VRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEERRLV
HRDLAARNVLVKSPNHVKITDFGLARLLEGDEKEYNADGGKMPIKWMALECIHYRKFTHQ
SDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMVMVKCWMID
ADSRPKFKELAAEFSRMARDPQRYLVIQGDDRMKLPSPNDSKFFQNLLDEEDLEDMMDAE
EYLVPQAFNIPPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSVP
YRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRKPVAPHVQEDSSTQRYSADPTVFAPERS
PRGELDEEGYMTPMRDKPKQEYLNPVEENPFVSRRKNGDLQALDNPEYHNASNGPPKAED
EYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQ
EYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>